n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. - Université de Bretagne Occidentale Access content directly
Journal Articles New England Journal of Medicine Year : 2012

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

Jackie Bosch
  • Function : Author
Hertzel C Gerstein
  • Function : Author
Gilles R Dagenais
  • Function : Author
Leanne Dyal
  • Function : Author
Hyejung Jung
  • Function : Author
Aldo P Maggiono
  • Function : Author
Jeffrey Probstfield
  • Function : Author
Ambady Ramachandran
  • Function : Author
Matthew C Riddle
  • Function : Author
Lars E Rydén
  • Function : Author


BACKGROUND: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown. METHODS: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here. RESULTS: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups. CONCLUSIONS: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).

Dates and versions

hal-00931578 , version 1 (15-01-2014)



Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, et al.. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.. New England Journal of Medicine, 2012, 367 (4), pp.309-18. ⟨10.1056/NEJMoa1203859⟩. ⟨hal-00931578⟩
51 View
0 Download



Gmail Mastodon Facebook X LinkedIn More